-
Founded in:
1996-11-27 -
Country:
China -
Address:
No. 378, Jianlu Road, Pudong New Area, Shanghai -
Tax NO.:
91310000630459924R -
Registered Funds:
1,341,172,692 yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Gliclazide |
The second-generation sulfonylurea hypoglycemic drugs selectively act on pancreatic islet cells, promote insulin secretion and increase insulin release after ingesting glucose, inhibit liver glucose production and output; reduce platelet aggregation and adhesion, and help prevent and treat diabetic microangiopathy.
More
The second-generation sulfonylurea hypoglycemic drugs selectively act on pancreatic islet cells, promote insulin secretion and increase insulin release after ingesting glucose, inhibit liver glucose production and output; reduce platelet aggregation and adhesion, and help prevent and treat diabetic microangiopathy. |
80mg | 21187-98-4 | 23 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Naftopidil dihydrochloride |
A selective α1 receptor antagonist that can inhibit the rise in blood pressure caused by α1 receptors. It has a hypotensive effect on a variety of hypertensive animal models, with a long duration of hypotensive effect, and does not cause reflex tachycardia during hypotensive treatment. No obvious first-dose effect or drug resistance was observed after multiple oral administrations. It can reduce the total peripheral resistance of anesthetized open-chest dogs, dilate peripheral blood vessels, and has no significant effect on cardiac output. It can also relieve the sympathetic tension of the prostate and urethra caused by the excitement of the receptor through the α1 receptor blocking effect, reduce the intraurethral pressure, and improve symptoms such as urination disorders caused by benign prostatic hyperplasia.
More
A selective α1 receptor antagonist that can inhibit the rise in blood pressure caused by α1 receptors. It has a hypotensive effect on a variety of hypertensive animal models, with a long duration of hypotensive effect, and does not cause reflex tachycardia during hypotensive treatment. No obvious first-dose effect or drug resistance was observed after multiple oral administrations. It can reduce the total peripheral resistance of anesthetized open-chest dogs, dilate peripheral blood vessels, and has no significant effect on cardiac output. It can also relieve the sympathetic tension of the prostate and urethra caused by the excitement of the receptor through the α1 receptor blocking effect, reduce the intraurethral pressure, and improve symptoms such as urination disorders caused by benign prostatic hyperplasia. |
57149-07-2 | 13 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Azithromycin |
Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. The mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of the bacterial ribosome and inhibiting RNA-dependent protein synthesis.
More
Azithromycin is a 15-membered macrolide antibiotic. In vitro tests have shown that azithromycin has antibacterial effects on a variety of common clinical pathogens, including Gram-positive aerobic bacteria, Gram-negative aerobic bacteria, anaerobic bacteria, sexually transmitted disease microorganisms and other microorganisms. The mechanism of action is the same as that of erythromycin, mainly binding to the 50S subunit of the bacterial ribosome and inhibiting RNA-dependent protein synthesis. |
83905-01-5 | 39 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Bismuth subnitrate |
Dispersed microparticles can firmly adhere to the gastric and duodenal mucosa, forming a protective film and promoting mucosal regeneration.
More
Dispersed microparticles can firmly adhere to the gastric and duodenal mucosa, forming a protective film and promoting mucosal regeneration. |
300mg | 1304-85-4 | 17 |
| Sodium bicarbonate |
It is an antacid together with magnesium carbonate, which can neutralize stomach acid and relieve stomach burning and stomach pain caused by excessive stomach acid.
More
It is an antacid together with magnesium carbonate, which can neutralize stomach acid and relieve stomach burning and stomach pain caused by excessive stomach acid. |
200mg | 144-55-8 | 44 |
| Magnesium carbonate |
It is an antacid together with sodium bicarbonate, which can neutralize stomach acid and relieve stomach burning and stomach pain caused by excessive stomach acid.
More
It is an antacid together with sodium bicarbonate, which can neutralize stomach acid and relieve stomach burning and stomach pain caused by excessive stomach acid. |
400mg | 546-93-0 | 12 |
| CORTEX FRANGULAE |
It is a laxative and can combat constipation caused by bismuth nitrate.
More
It is a laxative and can combat constipation caused by bismuth nitrate. |
25mg | 0 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Enalapril maleate |
This product is an angiotensin converting enzyme inhibitor. After oral administration, it is hydrolyzed into Enalaprilat in the body, which strongly inhibits angiotensin converting enzyme, reduces the content of angiotensin II, causes systemic vasodilation, and causes blood pressure reduction. It has a significant antihypertensive effect on rat models of renal hypertension II, renal hypertension I, and spontaneous hypertension.
More
This product is an angiotensin converting enzyme inhibitor. After oral administration, it is hydrolyzed into Enalaprilat in the body, which strongly inhibits angiotensin converting enzyme, reduces the content of angiotensin II, causes systemic vasodilation, and causes blood pressure reduction. It has a significant antihypertensive effect on rat models of renal hypertension II, renal hypertension I, and spontaneous hypertension. |
76095-16-4 | 35 |